Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein

Journal of Clinical Hypertension

Volumn 10, Issue 9, 2008, Pages 677-683

  Magen, Eli ^a   Mishal, Joseph ^a   Paskin, Jana ^a   Glick, Zahava ^a   Yosefy, Chaim ^a   Kidon, Mona ^b   Schlesinger, Menachem ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESISTANT ARTERIAL HYPERTENSION; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; COMPARATIVE STUDY; FOLLOW UP; HOSPITALIZATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTOMETRY; PHYSIOLOGY; PROGNOSIS; RETROSPECTIVE STUDY;

BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; COMPLEMENT C3; COMPLEMENT C4; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 58249086869     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.00002.x     Document Type: Article

References (34)

1. Moser M, Setaro J. Resistant or difficult to control hypertension. N Engl J Med. 2006;355:385-392.
2. Cifkova R, Erdine S, Fagard R. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens. 2003;21:1779-1786.
3. Thorand B, Lowel H, Schneider A, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: Results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med. 2003;163:93-99.
4. Freeman DJ, Norrie J, Caslake MJ, et al. West of Scotland Coronary Prevention Study: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51:1596-1600.
5. Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: The Cardiovascular Health Study. Diabetes. 2001;50:2384-2389.
6. Han TS, Sattar N, Williams K, et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002;25:2016-2021.
7. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study. Lancet. 1999;353:1649-1652.
8. Ford ES. Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol. 2002;155:57-64.
9. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
10. Bozzoli C, Muscari A, Puddu GM, et al. Association of serum C3 and essential hypertension. G Ital Cardiol. 1992;22(12):1361-1366.
11. Schaadt O, Sorensen H, Krogsgaard AR. Association between the C3F-gene and essential hypertension. Clin Sci (Lond). 1981;61(suppl 7):363s-365s.
12. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913-919.
13. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002;106:1439-1441.
14. Vongpatanasin W, Thomas GD, Schwartz R, et al. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation. 2007;115(8):1020-1028.
15. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;105:1890-1896.
16. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005;46(5):1118-1222.
17. Magen E, Viskoper R, Mishal J, et al. Resistant arterial hypertension and hyperlipidemia: Atorvastatin, not vitamin C, for blood pressure control. Isr Med Assoc J. 2004;6(12):742-746.
18. Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of lowdensity lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Rationale and design of the JUPITER trial. Circulation. 2003;108:2292-2297.
19. Ritchie RF, Palomaki GE, Neveux LM, et al. Reference distributions for complement proteins C3 and C4: A practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal. 2004;18:1-8.
20. Moshage H. Cytokines and the hepatic acute phase response. J Pathol. 1997;181:257-266.
21. Gabrielsson BG, Johansson JM, Lonn M, et al. High expression of complement components in omental adipose tissue in obese men. Obes Res. 2003;11:699-708.
22. Engstrom G, Hedblad B, Berglund G, et al. Plasma levels of complement C3 is associated with development of hypertension: A longitudinal cohort study. J Hum Hypertens. 2007;21(4):276-282.
23. Tomaszewski M, Zukowska-Szczechowska E, Grzeszczak W. Evaluation of complement component C4 concentration and immunoglobulins IgA, IgG, and IgM in serum of patients with primary essential hypertension. Pol Arch Med Wewn. 2000;103(5-6):247-251.
24. Palikhe A, Sinisalo J, Seppänen M, et al. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol. 2007;99(7):890-895.
25. Alper CA, Johnson AM, Birtch AG, et al. Human C'3: Evidence for the liver as the primary site of synthesis. Science. 1969;163(864):286-288.
26. Kulics J, Colten HR, Perlmutter DH. Counterregulatory effects of interferon-gamma and endotoxin on expression of the human C4 genes. J Clin Invest. 1990;85(3):943-949.
27. Ueki A, Sai T, Oka H, et al. Biosynthesis and secretion of the third component of complement by human endothelial cells in vitro. Immunology. 1987;61(1):11-14.
28. Ueda Y, Nagasawa K, Tsukamoto H, et al. Production of the third and fourth component of complement (C3, C4) by smooth muscle cells. Immunology. 1996;89(2):183-188.
29. Lin ZH, Fukuda N, Jin XQ, et al. Complement 3 is involved in the synthetic phenotype and exaggerated growth vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension. 2004;44:42-47.
30. Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
31. Cushman WC, Ford CE, Cutler JA. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404.
32. Black HR, Elliott WJ, Grandits G. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073-2082.
33. Julius S, Kjeldsen SE, Brunner H. VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens. 2003;16:544-548.
34. Salles GF, Fiszman R, Cardoso CR, et al. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension. 2007;50(4):723-728.